MondegarAI
GILEAD SCIENCES, INC. (GILD)

Q1 2025 · 13F-HR

GILEAD SCIENCES, INC. (GILD)holdings as filed

Filed 2025-05-13 · accession 0001123292-25-000217

$1.18B
Reported value
14
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
03940C100ACLXGBXARCELLX INC$440.9M37.3%6,720,803CommonSOLE
36315X101LKFTGALAPAGOS NV$419.4M35.5%16,707,477CommonSOLE
03969F109RCUSARCUS BIOSCIENCES INC$246.7M20.9%31,424,760CommonSOLE
045396207ASMBASSEMBLY BIOSCIENCES INC$21.1M1.79%2,209,471CommonSOLE
N5749R1002GHMERUS N V$19.0M1.61%452,527CommonSOLE
501976104KYTXKYVERNA THERAPEUTICS INC$8.0M0.67%4,126,119CommonSOLE
87583X109TNGXTANGO THERAPEUTICS INC$6.7M0.56%4,854,443CommonSOLE
98422T100XILIO THERAPEUTICS INC$6.6M0.56%9,105,451CommonSOLE
482929106KLRSKALARIS THERAPEUTICS INC$5.8M0.49%723,273CommonSOLE
43906K209HOOKHOOKIPA PHARMA INC$2.0M0.17%1,875,945CommonSOLE
019770106ALLOALLOGENE THERAPEUTICS INC$1.7M0.14%1,156,689CommonSOLE
52187K200CYPHLEAP THERAPEUTICS INC$1.6M0.14%5,319,148CommonSOLE
45175G108IKENA ONCOLOGY INC$1.5M0.13%1,159,145CommonSOLE
91864C107BRNSBARINTHUS BIOTHERAPEUTICS PL$359,7580.03%369,855CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.